Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Erasca, Inc.ERAS-4.770.001.69-1.21-40.33%-27.25%0.00$2.78$7.581,246,400$2.69

Detail of Erasca, Inc.

 
CEO
Dr. Jonathan E. Lim M.D.
Employees
126
Industry
Biotechnology
Sector
Healthcare
Market cap
$760M

Company details

Erasca Inc. is a clinical-stage biopharmaceutical company committed to eradicating cancer through precision oncology. At the forefront of innovative cancer treatment development, its primary focus lies in designing therapies that target key molecular drivers of cancer, particularly focusing on genetic mutations that significantly impact patient outcomes. Erasca's portfolio includes a range of investigational drugs that leverage cutting-edge molecular biology techniques aimed at addressing unmet medical needs in oncology. By concentrating on diverse therapeutic approaches, Erasca seeks to offer transformative benefits to patients across various cancer types. The company's dedication to precision medicine is underscored by its strategic collaborations and partnerships with leading research institutions and pharmaceutical firms, enhancing its capability to rapidly advance its drug candidates through clinical trials. Based in San Diego, California, Erasca Inc. plays a vital role in the life sciences sector, contributing to the future landscape of cancer treatment by pushing the boundaries of scientific research and therapeutic innovation.

Erasca, Inc.
ERAS • XNGS • US
$2.69
+0.62 (29.95%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.56
Margin profit
0.00%
52 week low
$1.79
52 week high
$3.28
50-day simple moving average
$0.00
200-day simple moving average
$2.78
Percent held by insiders
12.40%
Percent held by institutions
86.65%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ERAS +29.95%
eps change
ERAS 0.00%